Saturday 17 October 2026
Export ABSI’s income statement to Excel — free account
Absci Corporation
ABSI Healthcare Biotechnology
Absci Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, down 38.2% from fiscal 2024. In the quarter to June 2026, revenue fell 46.4%, EPS grew 12.5%, free cash flow fell 71.7% and total debt fell 93.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.25
0.63
−7.09%
Follow ABSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| (57.72%) | (63.89%) | (62.50%) | (55.68%) | ||
| (50.57%) | (55.34%) | (53.59%) | (47.73%) | ||
ROIC |
(174.74%) | (165.27%) | (163.37%) | (173.47%) | |
Return on Tangible Assets |
(58.95%) | (90.60%) | (78.00%) | (68.09%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 129.66 | |
Free Cash Flow per Share |
(0.69) | (0.64) | (0.68) | (0.56) | |
Free Cash Flow |
(108.80) | (97.30) | (92.72) | (80.06) | |
Capital Expenditures |
(0.71) | 0.09 | 0.21 | 0.65 | |
| Other line items | |||||
Cash ROIC |
(24.32%) | (32.64%) | (27.71%) | (21.04%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 5.39 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,540.49% | 4,593.08% | 2,907.79% | 2,644.69% | |
Selling, General and Administrative Expense of Revenue |
2,260.09% | 1,886.93% | 1,252.07% | 1,252.90% | |
Share Based Compensation of Revenue |
1,170.79% | 968.85% | 654.32% | 679.64% | |
Interest Coverage |
(1,342.54) | (834.01) | (575.68) | (411.94) | |
Operating CF/Net income |
0.89 | 0.82 | 0.81 | 0.70 | |
Depreciation/Fixed assets |
0.66 | 0.61 | 0.56 | 0.53 | |
Capex/Depreciation |
(0.06) | 0.01 | 0.02 | 0.05 | |
Revenue per Share |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF per Share |
(0.69) | (0.64) | (0.68) | (0.56) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.46 | (0.05) | (0.07) | (0.23) |
Columns are period end dates